Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown

Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip